Form 4: Co-Diagnostics Director James B. Nelson Acquires 110,000 Restricted Stock Units

Director James B. Nelson of Co-Diagnostics, Inc. reports the acquisition of 110,000 restricted stock units (RSUs) on April 26, 2024, under the company's 2015 Long Term Incentive Plan.

Summary

• On April 26, 2024, James B. Nelson, a director of Co-Diagnostics, Inc., acquired 110,000 Restricted Stock Units (RSUs).
• The RSUs were granted pursuant to the company's 2015 Long Term Incentive Plan, as amended.
• Each RSU represents the right to receive one share of Co-Diagnostics' common stock upon vesting.
• The RSUs will vest in six installments, starting on November 23, 2024, and continuing every six months thereafter.
• Following the transaction, Nelson directly owns 230,000 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices. The vesting schedule suggests a long-term commitment from the director.

Positives

• The grant of RSUs aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The vesting of the RSUs is contingent upon continued service, aligning the director's interests with the long-term performance of the company.

Industry Context

Equity compensation is a common practice in the biotech industry to attract and retain talent, aligning management's interests with shareholder value.

Stakeholder Impact

• The RSU grant aligns the director's interests with shareholders, potentially driving long-term value creation.

Key Dates